Target intelligence / Profile preview

GDNF family receptor alpha-4 (GFRA4)

Target
GFRA4
Molecular classification
Receptor, Cell surface glycosylphosphatidylinositol (GPI)-linked receptor, Co-receptor for receptor tyrosine kinase complex
01

Overview

GDNF family receptor alpha-4 (GFRA4) is a member of the glial cell line-derived neurotrophic factor receptor alpha family, functioning as a glycosylphosphatidylinositol (GPI)-linked cell surface receptor, most notably for the neurotrophic factor persephin. GFRA4 acts as a co-receptor for ligand-dependent activation of the receptor tyrosine kinase RET, supporting signal transduction important for neuronal survival, differentiation, and nervous system development[1][2][3][4]. It is implicated in disorders such as multiple endocrine neoplasia type 2, familial medullary thyroid carcinoma, and Hirschsprung disease; its aberrant expression or altered regulation may disrupt normal neurocrine signaling and developmental processes. GFRA4's precise physiological and pathophysiological roles continue to be elucidated, with a growing interest in how its modulation could influence disease outcomes in neurodevelopmental, neoplastic, and possibly immune-related conditions[1][2][3][4].

Other names
GFRA4GDNF receptor alpha-4Persephin receptorGFR-alpha-4GDNFR-alpha-4GFR receptor alpha 4GDNF family receptor alpha 4
02

Mechanism of action

Ligand-induced receptor activation: Persephin binds GFRA4, which acts as a co-receptor to activate the RET tyrosine kinase, initiating downstream signaling pathways important for cell survival, proliferation, and differentiation[2][4].

03

Biological functions

Signal transductionNeurotrophic signalingNervous system developmentCell proliferationNeuronal survival
04

Disease associations

CancerEndocrine neoplasias (e.g., Multiple endocrine neoplasia type 2)Thyroid carcinoma (familial medullary carcinoma)Neurodevelopmental disorders (e.g., Hirschsprung disease)Potentially immune/inflammatory diseases (e.g., asthma)
05

Safety considerations

Disruption of GFRA4 signaling may impact nervous system development and function; alterations implicated in developmental defects (e.g., Hirschsprung disease) and cancer, making on-target and off-target effects important safety considerations for any potential therapies[1][2].
06

Interacting drugs

None known; no small molecule drugs currently target GFRA4 directly[1][2][4].
07

Biomarkers

No established clinical biomarkers for GFRA4 at present. GFRA4 expression itself may serve as a biomarker in research settings for neural and endocrine-related pathologies[1][2].

Beyond the preview

Go deeper on GDNF family receptor alpha-4 (GFRA4).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on GDNF family receptor alpha-4 (GFRA4).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call